Mutations at the Boundary of the Hinge and Ligand Binding Domain of the Androgen Receptor Confer Increased Transactivation Function
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The androgen receptor (AR), a member of the steroid receptor superfamily of nuclear transcription factors, mediates androgen signaling in diverse target tissues. Here we report AR gene mutations identified in human prostate cancer and the autochthonous transgenic adenocarcinoma of the mouse prostate model that colocate to residues (668)QPIF(671) at the boundary of the hinge and ligand-binding domain, resulting in receptors that exhibit 2- to 4-fold increased activity compared with wild-type AR in response to dihydrotestosterone, estradiol, progesterone, adrenal androgens, and the AR antagonist, hydroxyflutamide, without an apparent effect on receptor levels, ligand binding kinetics, or DNA binding. The expression of these or similar variants could explain the emergence of hormone refractory disease in a subset of patients. Homology modeling indicates that amino acid residues (668)QPIF(671) form a ridge bordering a potential protein-protein interaction surface. The naturally occurring AR gene mutations reported in this study result in decreased hydrophobicity of this surface, suggesting that altered receptor-protein interaction mediates the precocious activity of the AR variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A signature motif in transcriptional co-activators mediates binding to nuclear receptors
Heery, D. M., Kalkhoven, E., Hoare, S., & Parker, M. G. (1997) · Nature · doi:10.1038/42750 · Cited by 2,128 · cited 1×
“The best characterized of these are the p160 coactivators glucocorticoid receptor-interacting protein 1 (GRIP1), steroid receptor coactivator 1 (SRC1), and amplified in breast cancer-1 (AIB1) (24–26), which contain conserved LXXLL motifs (L for leucine and X for any amino acid) termed LX domains (LXDs), that confer hi…”
BackgroundStructural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Ding, X. F., Anderson, C. M., Ma, H., Hong, H., Uht, R. M., Kushner, P. J., & Stallcup, M. R. (1998) · Molecular Endocrinology · doi:10.1210/mend.12.2.0065 · Cited by 434 · cited 1×
“The best characterized of these are the p160 coactivators glucocorticoid receptor-interacting protein 1 (GRIP1), steroid receptor coactivator 1 (SRC1), and amplified in breast cancer-1 (AIB1) (24–26), which contain conserved LXXLL motifs (L for leucine and X for any amino acid) termed LX domains (LXDs), that confer hi…”
Background
Cited by
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
“Even in the TRAMP (transgenic adenocarcinoma of mouse prostate) model of prostate cancer, in which SV40 large T antigen is overexpressed in the prostate luminal epithelial cells, mutations in the AR frequently develop, and different types of mutation are found in castrated versus intact mic”
BackgroundScher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Human prostate cancer risk factors
Bostwick, D. G., Burke, H. B., Djakiew, D., Euling, S., Ho, S.-M., Landolph, J., Morrison, H., Sonawane, B., Shifflett, T., Waters, D. J., et al. (2004) · Cancer · doi:10.1002/cncr.20408 · Cited by 650
Danila, D. C., Morris, M. J., de Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., Taplin, M.-E., Bubley, G. J., Kheoh, T., Haqq, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9259 · Cited by 410
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M. M., Harris, J. M., Jindal, S., Segara, D., Jia, L., Moore, N. L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0452 · Cited by 405
Self-citationA surface on the androgen receptor that allosterically regulates coactivator binding
Estébanez-Perpiñá, E., Arnold, L. A., Nguyen, P., Rodrigues, E. D., Mar, E., Bateman, R., Pallai, P., Shokat, K. M., Baxter, J. D., Guy, R. K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708036104 · Cited by 307
Chmelar, R., Buchanan, G., Need, E. F., Tilley, W., & Greenberg, N. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22365 · Cited by 255
Self-citationThe role of androgen receptor mutations in prostate cancer progression.
Brooke, G., & Bevan, C. (2009) · Current Genomics · doi:10.2174/138920209787581307 · Cited by 181
“activity and reduced ligand specificity compared to the wildtype receptor without changes in receptor levels, ligand binding or DNA binding [78].”
BackgroundHaelens, A., Tanner, T., Denayer, S., Callewaert, L., & Claessens, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1701 · Cited by 153
Verrijdt, G. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00003-9 · Cited by 148
Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif
Jehle, K., Cato, L., Neeb, A., Muhle-Goll, C., Jung, N., Smith, E. W., Buzon, V., Carbó, L. R., Estébanez-Perpiñá, E., Schmitz, K., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.534859 · Cited by 53
“80), (41-80) and (61-80) were generated by PCR amplification of Bag-1L and cloned into the pGex4T.”
BackgroundMethodInfluential
Metadata
- Authors
- Buchanan, G.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2001-01-01
- Volume
- 15
- Issue
- 1
- Pages
- 46-56
- ISSN
- 0888-8809 (ISSN-L)
- OpenAlex
- W2095649647
- Cited by
- 122
- References
- 3
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.